课题基金 / 基金详情

Novel Markers of Treatment Responsiveness for Pediatric Acute Asthma Exacerbations

Novel Markers of Treatment Responsiveness for Pediatric Acute Asthma Exacerbations
小儿哮喘急性加重治疗反应性的新标志物
批准号:
10850297
负责人:
Nidhya Navanandan
金额:
$7.56万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-15 至 2024-08-31
关键词:
AccelerationAccident and Emergency departmentAccountingAcuteAcute Respiratory Distress SyndromeAddressAdrenal Cortex HormonesAirway ResistanceAsthmaAutomobile DrivingBiologicalBiological MarkersBiological Response Modifier TherapyBronchodilator AgentsCaringChildChildhoodChildhood AsthmaChronicClinicalClinical ResearchDevelopment PlansEffectivenessEmergency CareEmergency MedicineEmergency department visitEnrollmentEnsureEpithelial CellsFundingFutureGenesGoalsHomeHospitalizationIndividualInfrastructureInhalationInstitutionInterferonsK-Series Research Career ProgramsKnowledgeLaboratoriesLeadLeadershipLength of StayMeasuresMentorsMentorshipMethodsModelingMolecular GeneticsMorbidity - disease rateNasal EpitheliumNoseOscillometryOutcomeOutpatientsParentsPhysiciansPhysiologicalPositioning AttributePrediction of Response to TherapyPredictive AnalyticsProspective StudiesResearchResearch MethodologyResourcesScientistSpirometryTestingTherapeutic InterventionTimeTrainingTranslational ResearchValidationVariantWorkasthma exacerbationcareercareer developmentclinical practiceclinical predictive modelclinical predictorsdiagnostic biomarkerexperiencefeasibility trialhospital readmissionimprovedimproved outcomeindividualized medicineinnovationmortalitymultidisciplinarynovelnovel diagnosticsnovel markerpediatric emergencypersonalized approachpredictive modelingprospectivepulmonary functionresponseskillssuccesstargeted treatmenttherapy developmenttooltranscriptometranscriptome sequencingtranscriptomicstreatment responsetreatment strategyunnecessary treatment

项目摘要

项目成果

Nidhya Navanandan的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Acute asthma exacerbations are the primary cause of morbidity and mortality in children with asthma. Current treatment for acute asthma exacerbations in the pediatric Emergency Department (ED) follows an one- size-fits all approach including inhaled bronchodilators and systemic corticosteroids. However, treatment response to initial protocolized therapies is variable and unpredictable presenting a significant management challenge for ED clinicians. Unfortunately, the pathobiologic mechanisms driving treatment response remain unclear, and an effective method to predict treatment response does not exist. Thus, ED clinicians frequently struggle with treatment and disposition decisions leading to over-utilization of therapies, prolonged ED length of stay, and hospitalizations in responders, and delays in appropriate therapy for non-responders. The extensive variation and inefficiency in care highlights the critical need for tools to inform more precise and effective ED management strategies for acute asthma exacerbations. The nasal transcriptome and airway oscillometry (AOS) are novel biologic and physiologic markers with strong potential to address this unmet knowledge and practice gap. This proposal aims to apply an innovative biomarker-directed, individualized approach to ED asthma management by leveraging these novel markers to pursue the following specific aims: 1) determine the utility of AOS as an objective measure of ED treatment responsiveness; 2) identify airway endotypes of ED treatment responsiveness using nasal transcriptomics, and 3) derive and internally validate a clinical prediction rule incorporating clinical and historical factors, and biologic and physiologic markers to determine ED treatment responsiveness in children with acute asthma exacerbations. To achieve these aims, the candidate, Nidhya Navanandan, MD, will leverage an existing study infrastructure for enrolling children with acute asthma exacerbations in the ED, developed in conjunction with her mentors during her institutional career development award. As a pediatric emergency medicine physician, Dr. Navanandan is uniquely positioned to accomplish the proposed K23 research and training aims. Her long-term goal is to become an expert in clinical and translational research methods to improve the effectiveness of emergency care for pediatric asthma. Dr. Navanandan has developed a detailed career development plan consisting of mentorship, didactic coursework, and hands-on laboratory and research conduct experience in order to expand her knowledge and skills in leadership of prospective studies, discovery and application of novel markers for clinical practice, and predictive analytics. Dr. Navanandan has assembled a multidisciplinary team of mentors with extensive clinical and translational research experience and topical expertise in the above realms to ensure her success in achieving the stated specific aims and career goals. This proposal will allow Dr. Navanandan to transition to an independent physician-scientist and prepare her for future R01-funding.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.jaip.2022.12.033
发表时间: 2023-05
期刊: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
影响因子: 9.4
作者: [Navanandan, Nidhya, Thompson, Talia, Pyle, Laura, Florin, Todd A.]
通讯作者: Florin, Todd A.
Novel Markers of Treatment Responsiveness for Pediatric Acute Asthma Exacerbations
  • 批准号:
    10548194
  • 项目类别:
  • 资助金额:
    $18.87万
  • 财政年份:
    2022
  • 负责人:
    Nidhya Navanandan
  • 依托单位:
Novel Markers of Treatment Responsiveness for Pediatric Acute Asthma Exacerbations
  • 批准号:
    10348963
  • 项目类别:
  • 资助金额:
    $18.88万
  • 财政年份:
    2022
  • 负责人:
    Nidhya Navanandan
  • 依托单位: